Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2023-01-31 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于所属企业药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary's pharmaceutical product passing a regulatory consistency evaluation by the National Medical Products Administration (国家药品监督管理局). It details the drug's approval, background, market impact, and risk factors. The document is short (1255 characters) and does not contain financial statements or detailed financial data. It is an announcement about a regulatory approval event rather than a financial report or management discussion. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a voting result, board change, or capital update. The content is regulatory in nature, informing investors about a compliance and product approval event. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-01-31 Chinese
哈药集团股份有限公司关于注销2021年股票期权与限制性股票激励计划中部分股票期权的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the cancellation of certain stock options under the company's 2021 stock option and restricted stock incentive plan. It details board and supervisory approvals, legal opinions, and the impact of the cancellation on the company. The content focuses on corporate governance actions related to stock incentive plans and does not contain financial statements or quarterly/yearly financial results. It is not a full annual report, audit report, earnings release, or interim report. The document is a formal announcement of a corporate action related to stock options and incentive plans, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories and is a regulatory disclosure about corporate governance and stock incentive plan changes.
2023-01-18 Chinese
哈药集团股份有限公司独立董事关于公司九届三十三次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Harbin Pharmaceutical Group Co., Ltd. regarding specific board meeting matters related to the company's 2021 stock option and restricted stock incentive plan. It discusses the legality, compliance, and impact of stock option cancellations, repurchases, and the exercise of stock options and lifting of restrictions. The document references relevant laws and regulations and confirms the board's procedures and decisions. It is not a full financial report, earnings release, or regulatory filing but rather a formal board-related opinion on management and governance matters concerning stock incentives. This fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board decisions and senior management matters.
2023-01-18 Chinese
北京市天元律师事务所上海分所关于哈药集团股份有限公司2021年股票期权与限制性股票激励计划预留授予部分第一期行权与第一期解除限售相关事宜的法律意见
Regulatory Filings
2023-01-18 Chinese
北京市天元律师事务所上海分所关于哈药集团股份有限公司2021年股票期权与限制性股票激励计划注销部分股票期权及回购注销部分限制性股票相关事宜的法律意见
Regulatory Filings
2023-01-18 Chinese
哈药集团股份有限公司关于2021年股票期权与限制性股票激励计划第一次预留授予股票期权第一个行权期采用自主行权模式的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (1481 characters) regarding the exercise of stock options under a 2021 stock option and restricted stock incentive plan. It details the terms of the exercise period, number of options, exercise price, and restrictions on exercise timing. It is labeled as a "提示性公告" (a prompt or indicative announcement) and includes no financial statements or comprehensive financial data. It references disclosures to be made in periodic reports but itself is not a financial report. The document is an announcement about stock option exercise arrangements and related corporate actions, fitting best under Capital/Financing Update (CAP) as it relates to equity incentive plans and share issuance. It is not a full report, earnings release, or regulatory filing of another type.
2023-01-18 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.